PLPBP deficiency is a rare genetic metabolic epilepsy caused by pathogenic variants affecting both copies of PLPBP. The disorder interferes with the brain’s ability to maintain normal pyridoxal 5′-phosphate — PLP — homeostasis. PLP is the biologically active form of vitamin B6 and an essential cofactor for many neurological biochemical reactions.
PLPBP deficiency is important because severe seizures often begin in the newborn period, may respond poorly to standard antiseizure medicines and can improve rapidly with pharmacological pyridoxine or PLP. It is therefore part of the wider group of vitamin B6-dependent epilepsies.
What PLPBP does
PLPBP encodes pyridoxal phosphate homeostasis protein, previously called PROSC. Its exact biochemical role is complex, but the protein helps maintain the intracellular availability and safe handling of PLP.
PLP is chemically reactive. Cells need mechanisms that make it available to the enzymes that require it while preventing inappropriate reactions elsewhere. PLPBP contributes to that balance.
Why seizures occur
Many enzymes involved in neurotransmitter metabolism require PLP. Disruption of PLP homeostasis can therefore disturb the chemical systems that help regulate neuronal excitability.
The result can be severe early-onset epilepsy, often as part of a developmental and epileptic encephalopathy.
When do seizures begin?
Most reported affected children develop seizures in the neonatal period, often within the first days of life. However, later presentations have been described.
Some pregnancies may have been complicated by unusual fetal movements, prematurity or fetal distress, but these are not universal findings.
Seizure types
PLPBP deficiency can produce multiple seizure types, including focal, tonic, clonic and myoclonic seizures as well as prolonged seizures and status epilepticus.
Because newborn seizures can be subtle, EEG may identify seizure activity that is not obvious from outward movement alone.
Response to pyridoxine or PLP
A major clue is improvement after treatment with pyridoxine or pyridoxal 5′-phosphate. Some affected people respond better to one form than the other.
Response can be rapid, but it is not always complete. Many affected individuals still require one or more conventional antiseizure medicines in addition to vitamin B6 therapy.
Why response alone does not prove PLPBP deficiency
ALDH7A1 deficiency and PNPO deficiency can also produce pyridoxine- or PLP-responsive seizures. Several rarer metabolic disorders can do the same.
That means a response to vitamin B6 should trigger a search for the underlying cause rather than becoming the final diagnosis.
Diagnosis
The diagnosis is established by identifying pathogenic or likely pathogenic variants in both copies of PLPBP in a person with compatible clinical findings.
Testing may be performed through a neonatal epilepsy panel, developmental and epileptic encephalopathy panel, exome sequencing or genome sequencing.
Biochemical testing
Unlike ALDH7A1 deficiency, PLPBP deficiency does not have one widely used highly specific biomarker that establishes the diagnosis.
Specialist biochemical profiles may show abnormalities of vitamin B6-related or neurotransmitter metabolites, but results can overlap with other disorders and may be modified by treatment.
EEG
EEG findings vary and can include burst suppression, multifocal epileptiform discharges, abnormal background activity and other severe neonatal epilepsy patterns.
EEG can help measure treatment response and detect electrographic seizures, but no single EEG appearance is diagnostic of PLPBP deficiency.
MRI
Brain MRI can be normal or show non-specific abnormalities. The diagnosis is not defined by one characteristic structural lesion.
Imaging remains important because structural brain disorders, hypoxic-ischaemic injury, infection and other causes can present with similarly severe neonatal seizures.
Why early treatment matters
Early seizure control is particularly important during the newborn period, when prolonged or recurrent seizures occur during a critical stage of brain development.
GeneReviews emphasises prompt vitamin B6 treatment when PLPBP deficiency is suspected, while molecular testing is pursued.
Why deliberate withdrawal is discouraged in young infants
Historically, clinicians sometimes stopped vitamin B6 and waited for seizures to recur in order to prove dependency. Current GeneReviews guidance advises against this strategy in neonates and young infants.
If a child with suspected vitamin B6-dependent epilepsy is stable on treatment, deliberately provoking seizure recurrence can expose the brain to avoidable risk. Molecular confirmation is preferred.
The first treatment should be monitored
Pharmacological pyridoxine and PLP are not ordinary nutritional supplements. Initial treatment can cause sleepiness, hypotonia, respiratory depression or apnoea in some infants.
For that reason, first-dose treatment in a critically ill newborn should take place in a setting with appropriate cardiorespiratory monitoring and respiratory support available.
Long-term treatment
People with confirmed PLPBP deficiency generally require lifelong vitamin B6 therapy. Pyridoxine or PLP may be used depending on individual response, tolerance and specialist judgement.
Additional antiseizure medicines may still be required. Treatment is therefore based on both the metabolic diagnosis and the person’s continuing seizure pattern.
Development and cognition
Outcome is variable. Some affected children achieve good seizure control and relatively favourable development, while others have persistent developmental delay, intellectual disability, speech and language impairment or motor difficulties.
Factors influencing outcome include the specific genetic variants, prenatal effects, age at treatment, duration of uncontrolled seizures and whether there are associated neurological abnormalities.
Monitoring treatment
Long-term follow-up usually includes seizure review, developmental assessment and monitoring for adverse effects of vitamin B6 treatment.
Excessive chronic pyridoxine can cause peripheral neuropathy. High-dose PLP has been associated with liver toxicity in some vitamin B6-dependent epilepsies, so clinicians use the lowest effective dose and monitor according to the treatment used.
Inheritance
PLPBP deficiency is inherited in an autosomal-recessive pattern. Typically, each parent carries one altered copy of PLPBP without having the disorder.
Genetic counselling can explain recurrence risk, carrier testing and reproductive options for families.
How PLPBP differs from PNPO deficiency
Both conditions impair vitamin B6-related brain chemistry, but through different mechanisms. PNPO deficiency impairs conversion of vitamin B6 vitamers into PLP. PLPBP deficiency disrupts maintenance and handling of PLP within cells.
That biochemical difference is one reason response to pyridoxine versus PLP can vary and why genetic confirmation matters.
How PLPBP differs from ALDH7A1 deficiency
ALDH7A1-related epilepsy is primarily a disorder of lysine metabolism. Accumulating lysine-pathway metabolites inactivate PLP secondarily.
PLPBP deficiency instead affects PLP homeostasis directly. As a result, ALDH7A1-specific lysine-reduction therapies are not automatically appropriate for PLPBP deficiency.
Worldwide access
PLPBP deficiency is treatable, but the diagnosis may be missed where rapid genomic testing, neonatal EEG, specialist metabolic services or access to pharmaceutical-grade PLP are limited.
The clinical challenge is particularly important in low-resource settings because pyridoxine may be available while PLP or molecular testing is not. That can make a partial treatment response difficult to interpret.
The central point
PLPBP deficiency is a treatable vitamin B6-dependent metabolic epilepsy, but it is not interchangeable with PNPO or ALDH7A1 disease. Molecular diagnosis matters because the disorders differ in mechanism, treatment response and long-term management.
Related reading
Vitamin B6-Dependent Epilepsies →
PNPO Deficiency and Epilepsy →
Pyridoxine-Dependent Epilepsy (ALDH7A1) →
Metabolic Epilepsies →
Sources
Medical note: therapeutic pyridoxine and PLP require specialist supervision. High-dose vitamin B6 should not be used as a home diagnostic test.
Evidence checked: September 2026.